Category: clinical cancer research

Cancer paper pulled due to “identical text” from one published 6 days prior; author objects

ClinCancRes_ak16Clinical Cancer Research is retracting a paper on the immunosuppressive effects of glioma due to “evidence of duplicate and/or redundant publication.”

According to the retraction notice, the 2010 paper bore exceeding similarities to another one published by the same group of researchers six days prior. That second paper appeared in Molecular Cancer Therapeutics, which – like Clinical Cancer Research — is published by the American Association for Cancer Research. Apparently, a reader tipped off the AACR about the similarity.

The corresponding author on both papers, however, has objected to the decision: Continue reading Cancer paper pulled due to “identical text” from one published 6 days prior; author objects

Pfizer retracts another experimental cancer drug study

clin cancer researchPfizer has retracted another study involving an experimental cancer drug that later failed later-stage trials.

The study, published in Clinical Cancer Research in 2010, looked at which patients might respond to the drug, called figitumumab. Here’s the notice: Continue reading Pfizer retracts another experimental cancer drug study

Cancer researcher who threatened to sue Retraction Watch corrects another paper

aggarwalBharat Aggarwal, the MD Anderson researcher who has threatened to sue Retraction Watch for writing about issues in his papers, has corrected another study.

Here’s the notice for “Induction of Cell Cycle Arrest and Apoptosis by the Proteasome Inhibitor PS-341 in Hodgkin Disease Cell Lines Is Independent of Inhibitor of Nuclear Factor-κB Mutations or Activation of the CD30, CD40, and RANK Receptors:” Continue reading Cancer researcher who threatened to sue Retraction Watch corrects another paper

Cancer cell line mixup leads to retraction

ccr 9-15At team of researchers at MD Anderson Cancer Center has retracted a paper after realizing that the cell lines they were using weren’t what they thought they were.

Here’s the detailed notice: Continue reading Cancer cell line mixup leads to retraction

Papers on potential cancer drugs retracted for image manipulation

ccr 9-13A group of researchers at the Einstein College of Medicine in the Bronx, New York has retracted two papers for image manipulation.

The retraction notices for “PM02734 (Elisidepsin) Induces Caspase-Independent Cell Death Associated with Features of Autophagy, Inhibition of the Akt/mTOR Signaling Pathway, and Activation of Death-Associated Protein Kinase” and “The Phosphatase Inhibitor Menadione (Vitamin K3) Protects Cells from EGFR Inhibition by Erlotinib and Cetuximab” say the same thing: Continue reading Papers on potential cancer drugs retracted for image manipulation

A fifth retraction for former Pitt and Hopkins oncology researcher Getzenberg

ccrA cancer researcher whose work was the subject of a lawsuit has retracted his fifth paper, this one from 2004.

Robert Getzenberg, formerly of the University of Pittsburgh and Johns Hopkins, has had two papers on prostate cancer biomarkers retracted, and two on colon cancer. The newly retracted paper is about a potential bladder cancer biomarker.

Here’s the notice from Clinical Cancer Research: Continue reading A fifth retraction for former Pitt and Hopkins oncology researcher Getzenberg

Scientist whose work is “not fully supported by the available laboratory records” to retract 8 more papers

SK Manna
SK Manna

Yesterday, we reported that Sunil Kumar Manna, the head of immunology at India’s Centre for DNA Fingerprinting and Diagnostics, had retracted two papers for image problems.

Turns out Manna will be retracting eight more, he told us today. Here they are: Continue reading Scientist whose work is “not fully supported by the available laboratory records” to retract 8 more papers

Retractions three and four for Hopkins cancer biomarker group

ccrA group of cancer researchers formerly centered at Johns Hopkins have retracted two more studies. The previous two retracted papers — one of which was the focus of a lawsuit — were about prostate cancer, while the new retractions are of papers about colon cancer.

Here’s the notice for one paper: Continue reading Retractions three and four for Hopkins cancer biomarker group

Five retractions for cancer research team for manipulated figures

The International Journal of Cancer, a Wiley title, has retracted a pair of articles from a group at UT Southwestern Medical Center in Dallas, for image manipulation.

The papers, from the lab of Adi Gazdar, the W. Ray Wallace Distinguished Chair in Molecular Oncology Research who is known for his massive collection of human cancer cells, were published in 2005.

The first was titled “Aberrant methylation of Reprimo in human malignancies.” According to the retraction notice: Continue reading Five retractions for cancer research team for manipulated figures

Tenth Potti retraction appears, in Clinical Cancer Research

Anil Potti and his colleagues have retracted another paper, “Characterizing the Clinical Relevance of an Embryonic Stem Cell Phenotype in Lung Adenocarcinoma,” originally published in the December 15, 2009, issue of Clinical Cancer Research.

According to the notice: Continue reading Tenth Potti retraction appears, in Clinical Cancer Research